Intersect ENT, Inc. (NASDAQ:XENT) is reporting third quarter financial results on Monday 2nd November 2020, before market open.
According to analysts surveyed by Thomson Reuters, XENT is expected to report 3Q20 loss of $ 0.45 per share from revenue of $ 21.80 million.
For the full year, analysts anticipate top line of $ 80.39 million, while looking forward to loss of $ 1.98 per share bottom line.
The Company Outlook
Revenue for 3Q20 are expected in a range of $ 22.40 million ~ $ 22.80 million
Full Year 2020 topline are forecasted in a range of$ 115.00 million ~ $ 119.00 million
Click Here For More Historical Outlooks Of Intersect ENT, Inc.
Previous Quarter Performance
Intersect ENT, Inc. posted loss for the second quarter of $ 0.65 per share, from the revenue of $ 9.78 million. The quarterly revenues dropped 63.32 percent compared with the same quarter last year. Wall street analysts are predicting, XENT to report 2Q20 loss of $ 0.56 per share from revenue of $ 5.41 million. The bottom line results missed street analysts by $ 0.09 or 16.07 percent, at the same time, top line results outshined analysts by $ 4.37 million or 80.78 percent.
Stock Performance
On Friday, shares of Intersect ENT, Inc. has traded high as $ 15.79 and has cracked $ 15.19 on the downward trend, reaching $ 15.50 with volume of 293.10 thousand shares.
According to the previous trading day, closing price of $ 15.50, representing a 161.31 % increase from the 52 week low of $ 5.97 and a 50.41 % decrease over the 52 week high of $ 31.46.
The company has a market capital of $ 506.88 million and is part of the Healthcare sector and Medical Devices industry.
Recent Analyst recommendations
- On 8th October 2020, downgraded by JPMorgan Chase & Co. to Neutral from Overweight rating.
Conference Call
Intersect ENT, Inc. will be hosting a conference call at 8:30 AM eastern time on 2nd November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.intersectent.com
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting.
